179 related articles for article (PubMed ID: 23731739)
21. A Case of Lung Adenocarcinoma Resistant to Crizotinib Harboring a Novel EML4-ALK Variant, Exon 6 of EML4 Fused to Exon 18 of ALK.
Anai S; Takeshita M; Ando N; Ikematsu Y; Mishima S; Ishida K; Inoue K
J Thorac Oncol; 2016 Oct; 11(10):e126-8. PubMed ID: 27663401
[No Abstract] [Full Text] [Related]
22. Concomitant Presence of EGFR and ALK Fusion Gene Mutation in Adenocarcinoma of Lung: A Case Report and Review of the Literature.
Thumallapally N; Yu H; Farhan M; Ibrahim U; Odiami M
J Pharm Pract; 2018 Apr; 31(2):244-248. PubMed ID: 28438075
[TBL] [Abstract][Full Text] [Related]
23. ALK inhibitors in the treatment of advanced NSCLC.
Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
[TBL] [Abstract][Full Text] [Related]
24. [Research progress in non-small cell lung cancer with concomitant EML4-ALK fusion gene and EGFR gene mutation].
Zeng Z; Wu Y
Zhongguo Fei Ai Za Zhi; 2011 Nov; 14(11):880-4. PubMed ID: 22104224
[TBL] [Abstract][Full Text] [Related]
25. [A case report: an EML4-ALK positive lung adenocarcinoma diagnosed
with lymphoma previously].
Liu L; Heng W
Zhongguo Fei Ai Za Zhi; 2015 Feb; 18(2):89-91. PubMed ID: 25676402
[TBL] [Abstract][Full Text] [Related]
26. Concomitant Epidermal Growth Factor Receptor Mutation and EML4-ALK Fusion in a Patient with Multifocal Lung Adenocarcinomas.
Fan J; Dai X; Nie X
J Thorac Oncol; 2018 Mar; 13(3):e45-e48. PubMed ID: 29472061
[No Abstract] [Full Text] [Related]
27. Concomitant EGFR Mutation and EML4-ALK Rearrangement in Lung Adenocarcinoma Is More Frequent in Multifocal Lesions.
Fan J; Dai X; Wang Z; Huang B; Shi H; Luo D; Zhang J; Cai W; Nie X; Hirsch FR
Clin Lung Cancer; 2019 Jul; 20(4):e517-e530. PubMed ID: 31138506
[TBL] [Abstract][Full Text] [Related]
28. A novel EML4-ALK variant: exon 6 of EML4 fused to exon 19 of ALK.
Penzel R; Schirmacher P; Warth A
J Thorac Oncol; 2012 Jul; 7(7):1198-9. PubMed ID: 22706607
[TBL] [Abstract][Full Text] [Related]
29. [Relevance of molecular alterations in histopathologic subtyping of lung adenocarcinoma based on 2011 International Multidisciplinary Lung Adenocarcinoma Classification].
Liu B; Shi SS; Wang X; Xu Y; Zhang XH; Yu B; Lu ZF; Wang JD; Zhou XJ
Zhonghua Bing Li Xue Za Zhi; 2012 Aug; 41(8):505-10. PubMed ID: 23157740
[TBL] [Abstract][Full Text] [Related]
30. ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity.
Kimura H; Nakajima T; Takeuchi K; Soda M; Mano H; Iizasa T; Matsui Y; Yoshino M; Shingyoji M; Itakura M; Itami M; Ikebe D; Yokoi S; Kageyama H; Ohira M; Nakagawara A
Lung Cancer; 2012 Jan; 75(1):66-72. PubMed ID: 21757253
[TBL] [Abstract][Full Text] [Related]
31. Clinical Significance of Detecting Somatic Gene Mutations in Surgically Resected Adenosquamous Cell Carcinoma of the Lung in Japanese Patients.
Morodomi Y; Okamoto T; Takenoyama M; Takada K; Katsura M; Suzuki Y; Fujishita T; Kitahara H; Shimamatsu S; Kohno M; Tagawa T; Okano S; Taguchi K; Ichinose Y; Maehara Y
Ann Surg Oncol; 2015 Aug; 22(8):2593-8. PubMed ID: 25373537
[TBL] [Abstract][Full Text] [Related]
32. Non-small cell lung cancer with EML4-ALK translocation in Chinese male never-smokers is characterized with early-onset.
Guo Y; Ma J; Lyu X; Liu H; Wei B; Zhao J; Fu S; Ding L; Zhang J
BMC Cancer; 2014 Nov; 14():834. PubMed ID: 25407901
[TBL] [Abstract][Full Text] [Related]
33. Recurrence of lung adenocarcinoma after an interval of 15 years revealed by demonstration of the same type of EML4-ALK fusion gene.
Tsukamoto Y; Kanamori K; Watanabe T; Mikami K; Ieki R; Nakano T; Kajimoto K; Hirota S
Pathol Res Pract; 2014 Dec; 210(12):1112-6. PubMed ID: 25238939
[TBL] [Abstract][Full Text] [Related]
34. Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogene.
Fukui T; Yatabe Y; Kobayashi Y; Tomizawa K; Ito S; Hatooka S; Matsuo K; Mitsudomi T
Lung Cancer; 2012 Aug; 77(2):319-25. PubMed ID: 22483782
[TBL] [Abstract][Full Text] [Related]
35. Analysis of ERBB ligand-induced resistance mechanism to crizotinib by primary culture of lung adenocarcinoma with EML4-ALK fusion gene.
Kimura M; Endo H; Inoue T; Nishino K; Uchida J; Kumagai T; Kukita Y; Kato K; Imamura F; Inoue M
J Thorac Oncol; 2015 Mar; 10(3):527-30. PubMed ID: 25695223
[TBL] [Abstract][Full Text] [Related]
36. Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma.
Cai W; Lin D; Wu C; Li X; Zhao C; Zheng L; Chuai S; Fei K; Zhou C; Hirsch FR
J Clin Oncol; 2015 Nov; 33(32):3701-9. PubMed ID: 26416997
[TBL] [Abstract][Full Text] [Related]
37. Establishment of a Conditional Transgenic Mouse Model Recapitulating EML4-ALK-Positive Human Non-Small Cell Lung Cancer.
Pyo KH; Lim SM; Kim HR; Sung YH; Yun MR; Kim SM; Kim H; Kang HN; Lee JM; Kim SG; Park CW; Chang H; Shim HS; Lee HW; Cho BC
J Thorac Oncol; 2017 Mar; 12(3):491-500. PubMed ID: 27836576
[TBL] [Abstract][Full Text] [Related]
38. First case of combined small-cell lung cancer with adenocarcinoma harboring EML4-ALK fusion and an exon 19 EGFR mutation in each histological component.
Toyokawa G; Taguchi K; Ohba T; Morodomi Y; Takenaka T; Hirai F; Yamaguchi M; Seto T; Takenoyama M; Sugio K; Ichinose Y
J Thorac Oncol; 2012 Dec; 7(12):e39-e41. PubMed ID: 23154565
[No Abstract] [Full Text] [Related]
39. [Lung adenocarcinoma with concomitant EGFR mutation and ALK rearrangement].
Caliez J; Monnet I; Pujals A; Rousseau-Bussac G; Jabot L; Boudjemaa A; Leroy K; Chouaid C
Rev Mal Respir; 2017 May; 34(5):576-580. PubMed ID: 27646667
[TBL] [Abstract][Full Text] [Related]
40. Dual drive coexistence of EML4-ALK and TPM3-ROS1 fusion in advanced lung adenocarcinoma.
Zhu YC; Liao XH; Wang WX; Xu CW; Zhuang W; Wei JG; Du KQ
Thorac Cancer; 2018 Feb; 9(2):324-327. PubMed ID: 29251824
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
